Predictive Oncology Powered by the Microbiome
Predict cancer treatment toxicities 48-72 hours before clinical symptoms appear. Transform oncology from reactive symptom management to proactive, personalized care.
Treatment side effects are detected only after symptoms appear, leading to delayed interventions and worse patient outcomes.
Unexpected toxicities cause dose reductions, treatment delays, and protocol changes that compromise therapeutic effectiveness.
Standard protocols don't account for individual patient biology. Each patient's microbiome responds uniquely to treatment.
Biosyntropic AI provides an integrated software ecosystem that analyzes biological data to provide actionable, explainable clinical support. The platform is built on a "foundation model" architecture that learns universal biological patterns across multiple cancer types.
Identifies biological shifts that precede clinical symptoms by 48-72 hours, providing a critical window for prophylactic treatment. The system detects subtle changes in biological markers that are invisible to standard clinical observation, transforming reactive care into proactive intervention.
Quantifies a patient's "Resilience Score" to enable personalized radiation and chemotherapy schedules that maximize tumor control while minimizing damage to healthy tissue. Each treatment plan adapts dynamically based on the patient's biological response, ensuring the most effective care with the fewest side effects.
Utilizes advanced neural networking to model how changes in one biological compartment (such as the gut) can trigger inflammatory "cascades" in another (such as the skin). This cross-organ intelligence reveals hidden connections that drive treatment complications, enabling interventions at the source rather than the symptom.
Monitors the "synergy" between a patient's microbiome, immune system, and metabolic health to predict exactly when a patient is ready for their next cycle of care. By tracking recovery across multiple biological layers simultaneously, the platform ensures patients return to treatment at the optimal moment — not too early, not too late.
Predict radiation dermatitis and related toxicities before they manifest clinically.
Early detection of Hand-Foot Syndrome and gut-mediated toxicity risks across chemotherapy regimens.
Multi-treatment interaction modeling for patients undergoing complex combination protocols.
Production-validated. Clinically ready.
Early warning window
Response time
Test pass rate
Compliant deployment
Reduce treatment complications and improve patient outcomes with predictive intelligence.
Differentiate with predictive care capabilities that improve treatment adherence and patient experience.
Enhanced toxicity monitoring for oncology trials requiring real-time adverse event detection.
Reduce readmissions and treatment delays caused by preventable adverse events.
Led by Dr. Rahma Wehelie, PhD — a biochemistry researcher and breast cancer survivor — Biosyntropic AI was born from a deeply personal mission: ensuring no patient is blindsided by treatment toxicity.
Her firsthand experience with cancer treatment, combined with her expertise in biochemistry, drives the platform's focus on turning the body's own microbiome signals into actionable clinical intelligence.
Contact us to learn how Biosyntropic AI can bring predictive intelligence to your oncology practice.
awehelie@Juncos.AI